Kornimate/medical-research-clean huggingface dataset:
zirconia based fixed dental prostheses

Conditions: Zirconia Based Fixed Dental Prostheses

Summary: the objective of this prospective clinical study is to investigate the differences in the complication rates between tooth- and implant- supported zirconia based fixed dental prostheses (fdps) with at least 4 units. the null-hypothesis is that there is no difference in the complication rates between implant- supported and tooth- supported zirconia fdps.

the study aims to provide evidence regarding the clinical behaviour of long-span tooth- and implant-supported fdps.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * missing of at least two adjacent teeth in the maxilla or mandibular * sufficient oral hygiene exclusion criteria: * addiction to alcohol or drugs * severe craniomandibular disorders * severe systematic diseases * patients unable or unwilling to sign the informed consent form * untreated periodontitis

Keywords: prospective study chipping survival rate fracture resistance zirconia
continuous nmb in pcas

Conditions: Out-of-hospital Cardiac Arrest

Summary: the main purpose of this study is to test the hypothesis that continuous nmb could improve outcome in cardiac arrest patients treated with therapeutic hypothermia.


Eligibility criteria:
inclusion criteria: 1. adult (older than 19) 2. ohca with sustained rosc 3. comatose (i.e., not following commands) following rosc 4. undergoing targeted temperature management (ttm) 5. time of enrollment ≤ 6hrs from rosc exclusion criteria: 1. pre-existing dementia, brain injury, or dependence on others for adls (cpc \> 3) 2. traumatic etiology for cardiac arrest 3. protected population (pregnant, prisoner)
intraocular pressure in ocular hypertensives with scleral lens wear

Conditions: Ocular Hypertension

Summary: the purpose of this study is to determine if short-term wear of a spherical rigid contact lens, called a scleral lens, will raise intraocular pressure in ocular hypertensive patients.

this is a randomized, self-controlled study designed to compare effectiveness of a scleral lens on intraocular pressure. in this study, all participants have one eye randomly selected to wear the scleral lenses during study measurements and the other eye serves as the control, non-lens wearing eye.

Eligibility criteria:
inclusion criteria: * diagnosis of ocular hypertension (iop \>22 in each eye during at least two visits over the previous 3 years) * may have had cataract extraction and intraocular lens (iol) * not on topical medication for glaucoma * no history of alt/slt * any age, 18 years or older * history of contact lens wear (except scleral lenses), as long as they are willing to not wear their lenses the day of the study exclusion criteria: * on topical medication for glaucoma * eye disease * inability to wear scleral lenses * any intraocular surgery other than uncomplicated cataract extraction. * known allergy to proparacaine eye drops
a randomized pilot study to evaluate the effects of a short course of metformin versus no therapy in the period prior to hysterectomy for grade 1-2 adenocarcinoma of the endometrium in obese non-diabetic women

Conditions: Adenocarcinoma of the Endometrium

Summary: the purpose of this research is to determine the effects of metformin, a well tolerated drug widely prescribed for treatment of type 2 diabetes mellitus, on endometrium cancer patients.


Eligibility criteria:
inclusion criteria: * histological confirmed diagnosis of grade i or ii adenocarcinoma of the endometrium * must be obese as defined by a body mass index (bmi) greater than or equal to 30 kg/m2 * candidate for surgical removal of their uterus as part of their endometrial cancer treatment * subjects must have signed informed consent * age 42 - 65 years of age * electrocorticogram (ecog) performance status of 0 - 2 * history of adequate renal, liver, and bone marrow function: * hb: (adequate for surgical intervention, with transfusion if necessary) white blood cell (wbc): (normal range) * platelets: (180k/cmm) * liver function test(lfts): normal bilirubin (\<2.0mg/dl), ast/alt (2xuln) * renal function: creatinine less than 1.4 * female subjects must either not be of child-bearing potential or must have a negative urine pregnancy test within 7 days of randomization to metformin. subjects are considered not of child-bearing potential if they are surgically sterile or they are postmenopausal for greater than 12 months. exclusion criteria: * poorly differentiated cancer or any of the high-risk subtypes of endometrial cancer including serous, clear cell, or carcinosarcoma * history of diabetes mellitus type 1 or type 2. * receiving metformin prior to enrollment * known hypersensitivity to metformin. * unable to swallow and retain oral medication. * pregnant or lactating. * previous or concurrent malignancies, except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for \> 5 years * if the physician feels that the candidate is not suitable for the study, he/she will be excluded. * currently taking biguanides, sulfonylurea drugs, thiazolidinediones, insulin, or mtor or dpp-4 inhibitors or having taken any of these medications during the 12 weeks prior to study participation. * clinical symptoms of gastrointestinal obstruction or bleeding and consideration for immediate surgery or immediate neoadjuvant chemoradiation. * history of lactic or other metabolic acidosis. * uncontrolled infectious disease. * history of positivity for human immunodeficiency virus (hiv). * history of congestive heart failure requiring pharmacologic treatment. * history of excessive alcohol abuse, defined by a habitual intake of more than three drinks daily. * mal-absorption syndrome, disease affecting gastrointestinal function, or previous resection of the stomach or small bowel. * current use of medications for weight loss. * currently taking cimetidine, thiazide diuretics or cephalexin. if a patient needs some of these agents, alternative agents should be substituted.
a phase ii trial evaluating irinotecan plus 5fu/lv in patients with relapsed/refractory upper gi tumours

Conditions: Upper Gastrointestinal Tumours

Summary: the objective of this study is to assess the efficacy and toxicity of a 2 weekly regimen containing irinotecan combined with leucovorin-modified 5-fluorouracil in the setting of relapsed or refractory upper gastrointestinal tumours. patients with locally advanced or metastatic adenocarcinoma originating from the oesophagogastric junction, stomach or pancreas who have previously received chemotherapy and have either failed to respond or who have relapsed after an initial response will be eligible for treatment in this study. the response rate, failure-free survival and overall survival of treated patients with the two different regimes will be evaluated. toxicity and quality of life will also be monitored closely.


Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma or squamous cell carcinoma of the oesophagus, o-g junction, stomach and pancreas, not amenable to surgical resection. * bidimensionally measurable disease, or unidimensional measurable disease accessible by ct scanning, not within previously irradiated areas. * patients with progressive disease during previous chemotherapy treatment or within three months of stopping treatment. * at least one previous chemotherapy regimen, given at least 4 weeks prior to inclusion in this study. * no previous exposure to irinotecan. * adequate bone marrow function with platelets \>100 x 109/l; wbc \> 3 x 109/l; neutrophils \> 1.5 x 109/l at the time of study entry. * satisfactory renal function, serum creatinine 135 mol/litre * satisfactory liver function: * in the absence of liver metastases:- bilirubin \< 1.25n (n=upper limit of normal range) hepatic transaminases \< 2.5n prothrombin time \< 1.5n * in the presence of liver metastases:- bilirubin \< 1.5n hepatic transaminases \< 5n prothrombin time \< 1.5n * no uncontrolled medical condition * no previous malignant disease except for non-melanotic skin cancer or in-situ carcinoma of the uterine cervix. * ecog performance status of 0, 1 or 2. * predicted life expectancy of \> 3 months. * adequate contraceptive precautions * informed written consent exclusion criteria: * medical or psychiatric conditions resulting in inability of patient to give written consent. * ecog performance status \>2 * intracerebral metastases or meningeal carcinomatosis * unresolved bowel obstruction * uncontrolled angina pectoris, heart failure (new york heart classification 3 or 4). * pregnancy/lactation * previous malignancy other than adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ.
a real-life study to understand the use and effects of palbociclib in us patients with breast cancer

Conditions: Breast Cancer; Malignant Neoplasm of Breast

Summary: palbociclib, the first oral cdk4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (mbc), called hormone receptors positive (hr+)/ human epidermal growth factor receptor 2 negative (her2-) disease. palbociclib is given orally in combination with hormonal therapies. the purpose of this study is to better understand how palbociclib combination is used in real-life conditions and its clinical impact compared with hormonal therapy. the study will also evaluate how long patients take the different cdk 4/6 inhibitor drugs and whether using those drugs impacts the use of chemotherapy later. male and female patients aged 18 years old or more presenting the following conditions will be selected for the study: * hr+/her2- mbc * first treatment with palbociclib, hormonal therapy, or other cdk4/6 inhibitors after mbc diagnosis the study will use data without personal identity, which were obtained from medical records in routine clinical practice.


Eligibility criteria:
patients are eligible for the study if they were 18 years of age or older at mbc diagnosis, had hr+/her2- confirmed and initiated first line therapy (cdk4/6i, et, ct, or other) in the metastatic setting during the period from february 2015 through june 2022 or data cutoff.

Keywords: metastatic breast cancer cdk4/6 inhibitor real-world data retrospective observational study palbociclib overall survival
breech delivery skills. resident learning program

Conditions: Breech Presentation; Before Labor

Summary: breech delivery is one of the mail topic in emergency obstetrics for italian board of obstetrics and gynecology. formal frontal lecture and digital learning represent nowadays the two typical learning methods. a bedside evaluation it's not feasible due to rarity of such emergency, due to the common senior physicians involvement when it occurs, and due to medico-legal risks. mannequin scenario represents the best way of skill evaluation

residents will be recruited for "breech delivery" in two different ways. one group (20) will attend a formal frontal lecture on breech delivery of at least one hour. a second group matched for sex distribution, age, residency year (20) will receive a digital lecture. after one month the two groups will test their abilities on a low fidelity mannequin. the simulation session will be recorded and evaluated by 5 specialists in a blind way. during the simulation the main topics of breech extraction are recorded. all residents will receive a questionnaire identifying the subject, previous experience bedside or in a course, and the agreement for video recording and data analysis. after the simulation test they will receive a second questionnaire indicating improvement levels (using a kirkpatrick model and a 5-point likert scale).

Eligibility criteria:
inclusion criteria: residents in university of chieti medical school - exclusion criteria: none -

Keywords: breech, learning, mannequin
tavns for acute intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: this study aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (tavns) in patients with acute intracerebral hemorrhage (ich). the tavns intervention will be delivered using the bs-tvns800-1 transcutaneous electrical stimulation therapy device (kerfun, shanxi, china). a total of 186 patients will be randomly assigned in a 1:1 ratio to either the tavns group or the sham-tavns group. the primary outcome is the relative volume of perihematoma edema assessed on day 10-14 after randomization. adverse events associated with tavns therapy will be systematically evaluated to assess its safety profile.


Eligibility criteria:
inclusion criteria: 1. patients with spontaneous supratentorial intracerebral hemorrhage. 2. age between 18 and 80 years. 3. onset within 72 hours. 4. hematoma volume between 5 and 40 ml. 5. glasgow coma scale (gcs) score greater than 8. 6. written informed consent obtained from the patient or their legal representative. exclusion criteria: 1. secondary intracerebral hemorrhage (e.g., traumatic, tumor-related, vascular malformation, aneurysm, or coagulopathy-related). 2. primary intraventricular hemorrhage. 3. parenchymal hemorrhage that ruptures into the ventricles, with blood completely filling one lateral ventricle, the third ventricle, the fourth ventricle or more than half of both lateral ventricles. 4. progressive neurological or other severe diseases. 5. planned surgical treatment within 24 hours. 6. pre-existing disability caused by previous illnesses: modified rankin scale (mrs) score ≥ 3. 7. patients with severe cardiomyopathy, heart failure, pacemaker implantation, atrial fibrillation, frequent premature beats, second-degree or higher atrioventricular block, or other severe arrhythmias. 8. severe pulmonary disease, liver disease, renal insufficiency (glomerular filtration rate \< 30 ml/min), active gastrointestinal bleeding, or malignant tumors with an expected survival of less than 3 months. 9. patients with hyperthyroidism, hypothyroidism, syncope, epilepsy, multiple sclerosis, parkinson's disease, multiple system atrophy, or other known disorders affecting autonomic nervous function. 10. use of medications that interfere with autonomic function (e.g., beta-blockers, theophylline, tricyclic antidepressants, or steroids) within 7 days before screening. 11. patients who cannot tolerate tavns. 12. congenital or acquired ear abnormalities preventing tavns treatment. 13. inability to comply with 10 days of treatment. 14. pregnancy or within 30 days of delivery. 15. participation in another interventional clinical trial. 16. inability to obtain written informed consent from the participant or their legal representative.

Keywords: intracerebral hemorrhage tavns perihemtomal edema neuroinflammation secondary brain injury
clinical impacts of burnout syndrome among anesthesiology residents

Conditions: Burnout, Caregiver

Summary: this study aimed to determine the relationship between burnout levels and clinical performances of anesthesiology residents.

fifty-five second until fourth year anesthesiology residents, who were not on any mental medication treatment, were recruited consecutively and asked to fill out questionnaires which are; the maslach burnout inventory (mbi) questionnaire to assess burnout levels, best practice anesthesiologist questionnaire to assess positive clinical performance, anesthesiology residents' self-reported errors and quality of care questionnaire to assess negative clinical performance.

Eligibility criteria:
inclusion criteria: * second until fourth year anesthesiology residents * not on any mental medication treatment * willing to participate exclusion criteria: * on paid leave * rejected to become the sample * had their shift in 24 hours prior to this study

Keywords: anesthesiology burnout clinical performances residency
non-op management of ventral hernia patients

Conditions: Hernia, Ventral

Summary: ventral hernias are among the most common surgical diseases among patients.the natural history of patients with ventral hernias who are managed non-operatively is unknown. the aim of this prospective trial is to document the natural history of patients who are undergoing initially non-operative management. the investigators hypothesize that 1) the risk of emergency ventral hernia repair is low, 2) the risk of elective ventral hernia repair is high, and 3) patients managed non-operatively will develop increasing hernia size and symptom progression. this is a prospective observational study of all patients undergoing non-operative management at lbj general hospital. patients will be consented and then followed for 5 years. phone interviews will be done with these patients yearly to assess surgical and medical history, information about their hernia, including pain level due to the hernia, as well as function and quality of life.


Eligibility criteria:
inclusion criteria: * all patients undergoing initial non-operative management as chosen by current practice patterns * all patients who opt for non-operative management due to personal choice, lack of symptoms or concerns regarding surgical risks. * age 18 or older exclusion criteria: * patient meets surgery criteria but elects for surgery within 1 year due to personal scheduling * patient smokes \< 1 pack per day, is actively quitting smoking, and desires to follow-up within 3 months upon smoking cessation * patient with bmi \< 35 kg/m2, is actively losing weight, and desires to follow-up within 3 months upon weight loss goals being met * patient is unlikely to be able to follow-up due to no personal or home phone * patient is enrolled in another trial

Keywords: non-operative management
'penny', a sms text-based chatbot intervention for medication adherence and side effect management among patients with gi cancers

Conditions: Gastrointestinal Cancer

Summary: there has been a dramatic paradigm shift over the last 25 years within cancer care due to the onset of many new targeted therapies and a transition from inpatient to outpatient care. hand in hand with this shift has been the increased development and use of oral anti-cancer drugs, including cytotoxic chemotherapies that patients self-administer at home versus administration of an intravenous product at an infusion center. one of the main drivers for the growth and popularity of oral chemotherapy has been patient preference. however, an incorrect assumption exists among patients that oral therapy is associated with minimal side effects. according to the 2008 nccn task force report on oral chemotherapy, "some patients may incorrectly assume that oral chemotherapy is not "real" chemotherapy and is more akin to taking a vitamin or antibiotic. furthermore, patients must understand that oral equivalents of cytotoxic therapies, such as capecitabine, have side effects that are similar to their parenteral counterparts in this case, fluorouracil. the need to monitor for side effects and titrate dosages increases the complexity of oral chemotherapy regimens". self-administration of these complex oral therapies causes patients to become more autonomous in their care, without medical supervision of doses between office visits. due to the lack of oversight, there is a concern of compromised efficacy if patients take less than the prescribed doses, or increased, sometimes life-threatening, toxicity, often between office visits, if more than the prescribed dose is taken. both daily dose and schedule can be complicated for patients to comprehend and follow. capecitabine is a particularly complex oral chemotherapy, with 2 pill dose sizes, dosing by body surface area (bsa), twice a day dosing, and days of on therapy and days off of therapy. for this reason, capecitabine has been chosen as the backbone for regimens that will be studied. as noted in section 5.3 capecitabine might be combined with other oral chemotherapies, parenteral chemotherapy or radiation therapy. the investigators believe there is an opportunity in this space to improve oral chemotherapy adherence by walking patients through how and when to take their oral therapies remotely, as well as to better manage toxicity by gathering more information from the patient during their treatment.


Eligibility criteria:
inclusion criteria: * adults (age \>18 years) with a diagnosis of a gi cancer, that is receiving one of the below treatments: * capecitabine only * capecitabine concurrent with radiation therapy * capecitabine with temozolomide * capecitabine with oxaliplatin * capecitabine with mitomycin and concurrent radiation therapy exclusion criteria: -
advancing hiv prevention and linkage to care among msm with gamification

Conditions: HIV Infections; Sexually Transmitted Diseases

Summary: this study is a pilot evaluation of 'stick to it', a behavioral intervention based on the concept of gamification. the objective of the program is to encourage young men who have sex with men (msm) to be regularly screened for hiv and sexually transmitted infections (stis) and to adopt safer sexual behaviors, with the ultimate goal to decrease hiv and sti incidence. gamification is the application of game elements, like points, badges, and rewards, to non-game settings.

the investigators will conduct a quasi-experimental pilot study of 'stick to it', a prevention intervention that uses gamification principles and mechanics. the intervention includes an online timer that reminds men to get tested, online quizzes, and peer recruitment; these activities are awarded with points redeemable for chances at prizes at participating clinics. the intervention was designed based on findings from interviews with health staff and focus groups with young msm, and with input from a gamification consultant. the primary hypothesis is that the intervention will increase repeat hiv/sti testing among young msm. the intervention will be implemented at two sti clinics in oakland and los angeles, california in 2-week intervals for six months. the investigators will review medical records of exposed and unexposed young msm attending the same sti clinics to compare uptake of quarterly hiv testing and self-reported behavior after six months.

Eligibility criteria:
inclusion criteria: * 18-26 years of age * male * self-identify as gay / bisexual / queer * willing and able to provide informed consent to join the stick to it program * resident in one of several zip code areas surrounding the clinic exclusion criteria: * not a resident of one of included zip code areas
transport distraction osteogenesis for ramus-condyle unit

Conditions: Bilateral or Unilateral Deficient Ramus-condyle Unit

Summary: this study was done to evaluate the use of transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with unilateral or bilateral tmj ankylosis to correct the resultant deformity

10 patients with post ankylosis deficient ramus /condyle unit who underwent release procedure in the maxillofacial and plastic surgery department, faculty of dentistry, alexandria university, egypt. all patients were assessed clinically and by imaging using opg, lateral and pa cephalometry, and cone beam ct to assess the deficient ramus/condyle unit (rcu) then patients were operated using transport distraction osteogenesis to lengthen the rcu. then follow up of all patients both clinically and radiographically was adopted.

Eligibility criteria:
inclusion criteria: * post ankylosis deformity: bilateral or unilateral deficient ramus-condyle unit (rcu) after tmj release exclusion criteria: * mentally affected patients. * medically compromised patients. * post menopausal osteoporosis.